You are here: Home » Companies » News
Business Standard

Gland Pharma IPO price band at Rs 1,490-1,500, offer opens on Nov 9

Gland Pharma, which announced itsabout Rs 6,500 crore IPO, has set a price band of Rs 1,490-1,500 per share (face value of Rs one) and the issue will be open on November 9, an official said

Gland Pharma | IPO

Press Trust of India  |  Hyderabad 


Gland Pharma, which announced its

about Rs 6,500 crore Initial Public Offer (IPO), has set a price band of Rs 1,490-1,500 per share (face value of Rs one) and the issue will be open on November 9, a senior official of the city-based drug maker said on Wednesday.

Srinivas Sadhu, MD and CEO of Gland Pharma, said the company plans to raise up toRs 1,250 crore through issuance of fresh equity and allow its China-based promoter Fosun Pharma Industrial Pte Ltd and Gland Celsus Chemicals Pvt Ltd another shareholder to sell a part of their stake.

"The price band has been decided at Rs 1,490 to Rs 1,500.

At the top end of the price band the issue is Rs 6480 crore.

The primary issue size is Rs 1,250 crore.

The total secondary offer is about 22.5 per cent of the pre-issue capital with Fosun Group offering 12.5 per cent of the total pre-issue capital and the rest is coming from the other selling shareholders of 10 per cent," Sadhu told reporters in a press conference.

The total dilution is therefore 26.48 per cent at the top end of the price band, he added.

The anchor issue for institutional investors opens on November 6, while the issue will come on November 9 and the issue closes on November 11.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 04 2020. 14:44 IST